PBH Stock Analysis: Buy, Sell, or Hold?
PBH - Prestige Consumer Healthcare Inc.
$64.47
0.57 (0.89%)
▲
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Feb 05, 2026
5d
Get Alerted When PBH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PBH shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: PBH shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$81.45
Based on 5.0% avg growth
INTRINSIC VALUE TODAY
$50.57
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBH is currently trading at $64.47, which is considered fair relative to its 30-day fair value range of $62.40 to $65.55. The stock's valuation (Forward PE: 13.2) is in line with its historical norms (13.2). At these levels, the market is pricing in 0.2% annual earnings growth.
Technical Outlook: Technically, PBH is showing sideways momentum. The price is currently testing key support at $62.73. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $78.00 (+22.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PBH is showing sideways momentum. The price is currently testing key support at $62.73. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $78.00 (+22.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$62.40 -
$65.55
Company Quality Score
55/100
(HOLD)
Options IV Signal
3th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
80.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 3th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 22.1% below Wall St target ($78.00)
- BULLISH: Expecting earnings turnaround to 0.2% growth with -3.4% revenue growth
Fair Price Analysis
30-Day Fair Range
$62.40 -
$65.55
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$1.59
(2.5%)
Support & Resistance Levels
Support Level
$62.73
Resistance Level
$68.28
Current Trend
Sideways
Fundamental Context
Forward P/E (Next Year Est.)
13.22
Wall Street Target
$78.00
(+22.1%)
Revenue Growth (YoY)
-3.4%
Earnings Growth (YoY)
-21.1%
Profit Margin
18.1%
Valuation Premium vs History
+0.2% premium
PE vs Historical
13.2 vs 13.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.2%
(market-implied from PE analysis)
1-Year Target
$64.03
(+0%)
2-Year Target
$64.16
(+0%)
3-Year Target
$64.28
(+1%)
3-Yr Target (if PE normalizes)
(PE: 13→13)
PE COMPRESSION
$64.21
(+1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 6.0%)
$128.53
(+101%)
Base:
(SPY PE: 13.2, Growth: 6.0%)
$76.17
(+19%)
Bear:
(PE: 11.2, Growth: 6.0%)
$64.75
(+1%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 15.82 | Current EPS (TTM): $4.04
Bull Case
$84.12
(+32%)
Analyst growth 19.7%, PE expands to 17.4
Base Case
$76.47
(+20%)
Market implied 19.7%, PE stable at 15.8
Bear Case
$43.45
(-32%)
Severe decline -20.0%, PE contracts to 13.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 30, 2026 5:41 PM ET
Data refreshes hourly during market hours. Next update: 6:41 PM
Data refreshes hourly during market hours. Next update: 6:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$179 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$158 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$84 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 57 HOLD |
Advanced PBH Option Strategies
Professional options setups generated by AI based on today's PBH price and gamma walls.
